共 50 条
- [1] A multicenter, open-label, phase 1a study of HC-5404 in patients with advanced solid tumorsJOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)Dudek, Arkadiusz Z.O'Shaughnessy, JoycePiha-Paul, Sarina A.Uprety, DipeshKitchens, Benjamin LeeHutson, Thomas E.Rank, Brian H.Stokes, MichaelDudgeon, CrissySurguladze, DavidLightcap, EricDrees, JeremyHarrison, BenLi, RichardLaCayo, AshleyMattson, PauletteBose, NanditaKarim, DhaminaGargano, Michele AnneIglesias, Jose Luis
- [2] A phase 1b, open-label, safety, tolerability, and efficacy study of HC-7366 in combination with belzutifan in patients with advanced or metastatic renal cell carcinoma (NCT06234605).JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL) : TPS609 - TPS609Bupathi, ManojkumarGarmezy, BenjaminMckay, Rana R.Ornstein, Moshe C.Figlin, Robert A.Picus, JoelRank, Brian H.Barata, Pedro C.Hammers, Hans J.Hutson, Thomas E.Lam, Elaine T.Tykodi, Scott S.Zhao, SongEmamekhoo, HamidChisamore, Michael JonMattson, PauletteHolm, MeganIglesias, Jose LuisMotzer, Robert J.
- [3] An open-label phase 1b/2 study of surufatinib in combination with tislelizumab in subjects with advanced solid tumors.JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)Dasari, ArvindKauh, John S.Tucci, ChristopherNanda, ShivaniKania, Marek K.Carlisle, Jennifer W.Paulson, Andrew Scott
- [4] A Phase 1b, Open-Label, Safety, Tolerability, and Efficacy Study of HC-7366 in Combination with Belzutifan (WELIREG™) in Patients with Advanced or Metastatic Renal Cell Carcinoma, NCT06234605ONCOLOGIST, 2024, 29 : S13 - S13McKay, Rana R.Garmezy, BenBarata, PedroOrnstein, MosheShah, Neil J.Hammers, HansHutson, Thomas E.Chisamore, MichaelKarim, DhaminaMattson, PauletteLightcap, EricDrees, JeremyHarrison, BenHolm, MeganBose, NanditaThomas, Cherry T.Motzer, Robert J.
- [5] A FIRST-IN-HUMAN, MULTICENTER, PHASE 1/2, OPEN-LABEL STUDY OF XTX101 IN PATIENTS WITH ADVANCED SOLID TUMORSJOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A549 - A549Powderly, JohnNorman, TeleenDuncan, MeghanHuber, MartinO'Neil, JenniferPatel, EktaVandross, Andrae
- [6] A Phase 1a/b Open-Label, Dose-Escalation Study of Etigilimab Alone or in Combination with Nivolumab in Patients with Locally Advanced or Metastatic Solid TumorsCLINICAL CANCER RESEARCH, 2022, 28 (05) : 882 - 892Mettu, Niharika B.Ulahannan, Susanna, VBendell, Johanna C.Garrido-Laguna, IgnacioStrickler, John H.Moore, Kathleen N.Stagg, RobertKapoun, Ann M.Faoro, LeonardoSharma, Sunil
- [7] Open-Label, Multicenter, Phase 1 Study of Alisertib (MLN8237), an Aurora A Kinase Inhibitor, With Docetaxel in Patients With Solid TumorsCANCER, 2016, 122 (16) : 2524 - 2533Graff, Julie N.Higano, Celestia S.Hahn, Noah M.Taylor, Matthew H.Zhang, BinZhou, XiaofeiVenkatakrishnan, KarthikLeonard, E. JaneSarantopoulos, John
- [8] A Multicenter, Open-Label, Phase 1 Study Evaluating the Safety and Tolerability of Pegaspargase in Combination with Gemcitabine in Advanced Metastatic Solid Tumors and LymphomaCANCER INVESTIGATION, 2015, 33 (05) : 172 - 179Borad, Mitesh J.Babiker, Hani M.Anthony, StephenMita, MonicaBuchbinder, AbyKeilani, TahaGrem, Jean
- [9] Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 studyJOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (01)Shen, LinGuo, JunZhang, QingyuanPan, HongmingYuan, YingBai, YuxianLiu, TianshuZhou, QingZhao, JunShu, YongqianHuang, XiaomingWang, SiyangWang, JieZhou, AipingYe, DingweiSun, TingGao, YujuanYang, SiluWang, ZoubaiLi, JianWu, Yi-Long
- [10] A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY AND TOLERABILITY STUDY OF NC762 IN SUBJECTS WITH ADVANCED OR METASTATIC SOLID TUMORSJOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A781 - A781Myint, HanShah, SatishGutierrez, MartinZsiros, EmeseNelson, MeganZeidan, StephanieMyrthil, NadiaMorawski, AaronBarbu, AlinaShaik, JahangheerZhou, ChelseaKanellopoulou, ChrysiCopeland, RonCusumano, ZacharyFlies, DallasLangermann, SolomonLorusso, PatriciaOdunsi, Kunle